View Post

CDH1 Linked With New Hereditary Breast Cancer Syndrome

In In The News by Barbara Jacoby

By: Cristina Ferrario From: medscape.com BRCA is no longer the only gene that identifies hereditary breast cancer (BC) syndromes. Pathogenic variants of CDH1 identify a form of hereditary lobular BC (HLBC) that is unrelated to the better-known breast-ovarian syndrome linked to alterations in BRCA1 and BRCA2, according to a recent all-Italian study published in JAMA Network Open. “Pathogenic or likely pathogenic …

View Post

Ductal Carcinoma Quadruples Risk of Invasive Breast Cancer

In In The News by Barbara Jacoby

From: insideprecisionmedicine.com Women who are diagnosed with ductal carcinoma in situ (DCIS) are around four times as likely to develop invasive breast cancer and to die from breast cancer than women in the general population, according to a study published by The BMJ this week. This increased risk lasted for at least 25 years after diagnosis, suggesting that DCIS survivors …

View Post

New research calls into question relationship between cancer risk and depression, anxiety

In In The News by Barbara Jacoby

By: Drew Amorosi From: healio.com Key takeaways: Results showed no association between depression or anxiety and overall cancer risk. Other risk factors may explain the slightly elevated risk observed for smoking-related cancers. A meta-analysis performed by an international group of researchers revealed no association between depression or anxiety and increased overall cancer risk. Results showed elevated risk for smoking-related cancers …

View Post

Soliman Details Testing for and Treating HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Jordyn Sava From: targetedonc.com Over recent years, patients with HER2-positive metastatic breast cancer now have new therapies which have changed the treatment landscape in this space based on the completed and ongoing trials. The phase 3 CLEOPATRA study (NCT00567190), the efficacy and safety of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel was compared with placebo, trastuzumab, and docetaxel in patients …